Safety and efficacy of sequential chemotherapy with carboplatin plus gemcitabine followed by weekly paclitaxel in advanced non-small cell lung cancer

International Journal of Clinical Oncology

Volumn 18, Issue 6, 2013, Pages 988-996

  Soetekouw, Patricia M M B ^a,b   Timmer Bonte, Johanna N H ^a   Van Der Drift, Miep A ^a   Van Leeuwen, Frank ^c   Wagenaar, Michiel ^a,d   Van Die, Lya ^a,e   Bussink, Jan ^a   Tjan Heijnen, Vivianne C G ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c Integraal Kankercentrum Oost   (Netherlands)

^d MEDISCH SPECTRUM TWENTE   (Netherlands)

^e Harbour Hospital   (Netherlands)

Author keywords

Carboplatin; Gemcitabine; NSCLC; Paclitaxel; Sequential

Indexed keywords

CARBOPLATIN; GEMCITABINE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER FATIGUE; CANCER STAGING; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEASIBILITY STUDY; FEMALE; HUMAN; INCIDENCE; INTERSTITIAL PNEUMONIA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUROPATHY; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT DURATION; TREATMENT PLANNING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; TREATMENT OUTCOME;

EID: 84891495716     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-012-0476-7     Document Type: Article

References (73)

1. Mok TS, Wu YL, Thongprasert S et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957
2. Kim ES, Hirsh V, Mok T et al (2008) Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372:1809-1818
3. Herbst RS, Prager D, Hermann R et al (2005) TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23:5892-5899
4. Cappuzzo F, Ciuleanu T, Stelmakh L et al (2010) Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 11:521-529
5. Yang K, Wang YJ, Chen XR et al (2010) Effectiveness and safety of bevacizumab for unresectable non-small-cell lung cancer: a meta-analysis. Clin Drug Investig 30:229-241
6. Goffin J, Lacchetti C, Ellis PM et al (2010) First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review. J Thorac Oncol 5:260-274
7. Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550
8. Sandler A, Herbst R (2006) Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways. Clin Cancer Res 12:4421s-4425s
9. Reck M, von Pawel J, Zatloukal P et al (2009) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 27:1227-1234
10. Johnson DH, Fehrenbacher L, Novotny WF et al (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22:2184-2191
11. Pirker R, Pereira JR, Szczesna A et al (2009) Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 373:1525-1531
12. Lynch TJ, Patel T, Dreisbach L et al (2010) Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 28:911-917
13. (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 311:899-909
14. Manegold C, Bergman B, Chemaissani A et al (1997) Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer. Ann Oncol 8:525-529
15. Wozniak AJ, Crowley JJ, Balcerzak SP et al (1998) Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 16:2459-2465
16. Bonomi P, Kim K, Fairclough D et al (2000) Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 18:623-631
17. Fossella F, Pereira JR, von Pawel J et al (2003) Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 21:3016-3024
18. Sandler AB, Nemunaitis J, Denham C et al (2000) Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 18:122-130
19. Scagliotti GV, Parikh P, von Pawel J et al (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543-3551
20. Ohe Y, Ohashi Y, Kubota K et al (2007) Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 18:317-323
21. Lilenbaum RC, Herndon JE 2nd, List MA et al (2005) Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol 23:190-196
22. Zatloukal P, Petruzelka L, Zemanova M et al (2003) Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial. Lung Cancer 41:321-331
23. Gronberg BH, Bremnes RM, Flotten O et al (2009) Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 27:3217-3224
24. Helbekkmo N, Sundstrom SH, Aasebo U et al (2007) Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity. Br J Cancer 97:283-289
25. Carrato A, Alberola V, Massuti B et al (1998) Combination of gemcitabine and carboplatin as first line treatment in non-small cell lung cancer. In: 23rd Congress of the European Society for Medical Oncology, Athens, Greece, 6-10 November 1998 (abstr 431P)
26. Parente B, Barroso A, Conde S et al (2000) A randomized phase III study of gemcitabine and carboplatinum versus vinorelbine and carboplatinum in advanced non small-cells lung cancer (NSCLC). Lung Cancer 29(Suppl 1):61
27. Masters G, Argiris A, Hahn E et al (2006) A randomized phase II trial using two different treatment schedules of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer. J Thorac Oncol 1:19-24
28. Obasaju C, Ye Z, Bloss L et al (2005) Gemcitabine/carboplatin in patients with metastatic non-small cell lung cancer: phase II study of 28-day and 21-day schedules. Clin Lung Cancer 7:202-207
29. Delbaldo C, Michiels S, Syz N et al (2004) Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA 292:470-484
30. Fidias PM, Dakhil SR, Lyss AP et al (2009) Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 27:591-598
31. De Pas T, De Braud F, Danesi R et al (2000) Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in chemo-naïve patients with advanced non-small-cell lung cancer. Ann Oncol 11:821-827
32. Bunn PA Jr, Kelly K (1998) New chemotherapeutic agents prolong survival and improve quality of life in non-small-cell lung cancer: a review of the literature and future directions. Clin Cancer Res 4:1087-1100
33. Edelman MJ, Gandara DR, Lau DH et al (2001) Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: carboplatin and gemcitabine followed by paclitaxel. Cancer 92:146-152
34. Belani CP, Ramalingam S, Perry MC et al (2008) Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer. J Clin Oncol 20(26):468
35. Ramalingam S, Perry MC, La Rocca RV et al (2008) Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3-weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancer. Cancer 113:542-546
36. Rose W (1993) Taxol-based combination chemotherapy and other in vivo preclinical antitumor studies. Monogr Natl Cancer Inst 15:47-53
37. Akerley W, Herndon J, Egorin MJ et al (2003) Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B. Cancer 97:2480-2486
38. Akerley W, Choy H, Safran H et al (1997) Weekly paclitaxel in patients with advanced lung cancer: preliminary data from a phase II trial. Semin Oncol 24(4 Suppl 12):S12-10-S12-13
39. Akerley W, Glantz M, Choy H et al (1998) Phase I trial of weekly paclitaxel in advanced lung cancer. J Clin Oncol 16:153-158
40. Chang A, Rubins J, Asbury R et al (2001) Weekly paclitaxel in advanced non-small cell lung cancer. Semin Oncol 28(4 Suppl 14):10-13
41. (1997) Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 15:2996-3018
42. Mountain CF (1997) Revisions in the international system for staging lung cancer. Chest 111:1710-1717
43. Miller AB, Hoogstraten B, Staquet M et al (1981) Reporting results of cancer treatment. Cancer 47:207-214
44. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10
45. Gridelli C, Perrone F, Gallo C et al (2003) Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the multicenter Italian lung cancer in the elderly study (MILES) phase III randomized trial. J Natl Cancer Inst 95:362-372
46. Smith IE, O'Brian ME, Talbot DC et al (2001) Duration of chemotherapy in advanced non-small cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 19:1336-1341
47. Park JO, Kim SW, Ahn JS et al (2007) Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum based chemotherapy in non-small-cell lung cancer. J Clin Oncol 25:5233-5239
48. Socinski MA, Schell MJ, Peterman A et al (2002) Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 20:1335-1343
49. Von Plessen C, Bergman B, Andresen O et al (2006) Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer. Br J Cancer 95:966-973
50. Brodowicz T, Krzakowski M, Zwitter M, Central European Cooperative Oncology Group CECOG et al (2006) Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 52:55-63
51. Ciuleanu TE, Brodowicz T, Zielinski CC et al (2009) Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double blind, phase 3 study. Lancet 374:1432-1440
52. Edelman MJ, Clark JI, Chansky K et al (2004) Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel. Clin Cancer Res 10:5022-5026
53. Bridges BB, Thomas L, Hausner PF et al (2008) Phase II trial of gemcitabine/carboplatin followed by paclitaxel in patients with performance status=2,3 or other significant co-morbidity (HIV infection or s/p organ transplantation) in advanced non-small cell lung cancer. Lung Cancer 61:61-66
54. Chiappori A, Simon G, Williams C et al (2005) Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancer. Oncology 68:382-390
55. Clark JI, Kancharla K, Qamar R et al (2001) Pilot study of sequential vinorelbine and cisplatin followed by docetaxel for selected IIIB and stage IV non-small cell lung cancer. Lung Cancer 34:271-277
56. Hosoe S, Komuta K, Shibata K et al (2003) Gemcitabine and vinorelbine followed by docetaxel in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial of nonplatinum sequential triplet combination chemotherapy (JMTO LC00-02). Br J Cancer 88:342-347
57. Mok TS, Ho S, Chan G et al (2007) Sequential chemotherapy with combination irinotecan and cisplatin followed by docetaxel for treatment-naive patients with advanced non-small cell lung cancer. J Thorac Oncol 2:838-844
58. Ceribelli A, Pino MS, Gelibter AJ et al (2007) Sequential chemotherapy in nonsmall-cell lung cancer: cisplatin and gemcitabine followed by docetaxel. Cancer 109:727-731
59. Binder D, Schweisfurth H, Grah C et al (2007) Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial. Cancer Chemother Pharmacol 60:143-150
60. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182-1186
61. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70
62. Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139
63. de Laat WL, Jaspers NG, Hoeijmakers JH (1999) Molecular mechanism of nucleotide excision repair. Genes Dev 13:768-785
64. Rabik CA, Dolan ME (2007) Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33:9-23
65. Martin LP, Hamilton TC, Schilder RJ (2008) Platinum resistance: the role of DNA repair pathways. Clin Cancer Res 14:1291-1295
66. Lord RV, Brabender J, Gandara D et al (2002) Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 8:2286-2291
67. Azuma K, Komohara Y, Sasada T et al (2007) Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Sci 98:1336-1343
68. Rosell R, Danenberg KD, Alberola V et al (2004) Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 10:1318-1325
69. Holm B, Mellemgaard A, Skov T et al (2009) Different impact of excision repair cross-complementation group 1 on survival in male and female patients with inoperable non-small-cell lung cancer treated with carboplatin and gemcitabine. J Clin Oncol 27:4254-4259
70. Simon GR, Sharma S, Cantor A et al (2005) ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 127:978-983
71. Lee KH, Min HS, Han SW et al (2008) ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer. Lung Cancer 60:401-407
72. Zheng Z, Chen T, Li X et al (2007) DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 356:800-808
73. Olaussen KA, Dunant A, Fouret P et al (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355:983-991